Core Insights - A strategic cooperation agreement has been established among InSilico Medicine, Maiwei Biotech, and Haoyuan Pharmaceutical to develop a new library of ADC compounds targeting hundreds of antigens, aiming to accelerate the industrialization of innovative ADC drugs [1][2] Group 1: Company Contributions - Maiwei Biotech possesses an internationally leading ADC drug development platform that has been clinically validated, showcasing strong R&D capabilities and commercialization potential [1] - InSilico Medicine will utilize its Pharma.AI platform to design innovative payload-linkers based on disease mechanisms and target characteristics, demonstrating the advantages of AI in drug development [2] - Haoyuan Pharmaceutical will provide a rich resource library of molecular building blocks and tool compounds to support the synthesis of ADC payload-linkers, facilitating a full-process collaboration from screening to clinical development [2] Group 2: Industry Impact - This collaboration represents an innovative breakthrough in China's biopharmaceutical industry within the ADC drug sector, integrating AI technology with traditional drug development to create a new model for ADC drug development [2] - The partnership aims to significantly shorten the molecular optimization process, which traditionally takes years, thereby enhancing R&D efficiency [2] - The collaboration establishes a complete value chain for ADC drug development, maximizing the strengths of each party to efficiently advance innovation and provide more treatment options for global patients [2][3]